Browse Results

Select your format based upon: 1) how you want to read your book, and 2) compatibility with your reading tool. To learn more about using Bookshare with your device, visit the Help Center.

Here is an overview of the specialized formats that Bookshare offers its members with links that go to the Help Center for more information.

• Bookshare Web Reader - A customized reading tool for Bookshare members offering all the features of DAISY with a single click of the "Read Now" link.
• DAISY (Digital Accessible Information System) - A digital book file format. DAISY books from Bookshare are DAISY 3.0 text files that work with just about every type of access technology that reads text. Books that contain images will have the download option of ‘DAISY Text with Images’.
• BRF (Braille Refreshable Format) - Digital Braille for use with refreshable Braille devices and Braille embossers.
• MP3 (MPEG audio layer 3) - Provides audio only with no text. These books are created with a text-to-speech engine and spoken by Kendra, a high quality synthetic voice from Ivona. Any device that supports MP3 playback is compatible.
• DAISY Audio - Similar to the DAISY option above; however, this option uses MP3 files created with our text-to-speech engine that utilizes Ivonas Kendra voice. This format will work with Daisy Audio compatible players such as Victor Reader Stream and Read2Go.
• EPUB - A standard e-book format that can be read on many tools, such as iBooks, Readium or others.
• Word - Accessible Word output, which can be unzipped and opened in any tool that allows .docx files

Chemoradiation in Cancer Therapy (Cancer Drug Discovery and Development)

Internationally recognized experts in cancer biology and clinical research review the present status of the multimodality approach to the management of solid tumors and speculate on possible future strategies for chemoradiation therapy. The authors detail applications of combined modality therapy in lung, esophageal, breast, gastric, pancreatic, colon, and rectal cancers. They also show how radiation interacts with such chemotherapeutic agents as the platinum complexes, taxanes, and gemcitabine in the treatment of malignant gliomas, and head and neck cancer. A review of how to integrate new specific molecular targeted agents into multimodality therapy in the future.

Chemoreception: From Cellular Signaling to Functional Plasticity (Advances in Experimental Medicine and Biology #536)

Since 1959, the International Society of Arterial Chemoreception (ISAC) has organized in a variety of countries fifteen scientific meetings devoted to the mechanisms of peripheral arterial chemoreception and chemoreceptor reflexes. After the meeting held in Philadelphia with Sukhamay Lahiri as president, ISAC membership elected Lyon (CNRS, University Claude Bernard, France) as the site of the xv" ISAC Symposium. The Symposium was effectively held in Lyon from the 18th to the 22nd of November 2002 and Jean-Marc Pequignot was its president. The organizers were Jean-Marc Pequignot and Yvette Dalmaz Lyon (CNRS, University Claude Bernard, France) and the Scientific Committee was formed by John Carroll (University of Arkansas for Medical Sciences, USA), Constancio Gonzalez (University of Valladolid, Spain), Prem Kumar (University of Birmingham, U. K. ), Sukhamay Lahiri (University of Pennsylvania, Philadelphia, USA), Colin Nurse (McMaster University, Hamilton, Ontario, Canada), and Nanduri Prabhakar (Case Western University, Cleveland, Ohio, USA). The Symposium in Lyon intended to follow the path opened in Philadelphia gathering people working at the interface of cellular and molecular biology with researchers in the more classical topics of chemoreception pathways and reflexes. The aim was to join experts with different perspectives. Along these lines, some participants are engaged in the exploration of the intimate mechanisms of oxygen sensing and cellular responses, with their work centered in a great number of preparations covering a broad spectrum from bacteria, to chemoreceptor cells or to central nervous systems neurons.

Chemosensitivity: Volume I: In Vitro Assays (Methods in Molecular Medicine #110)

A state-of-the art collection of readily reproducible laboratory methods for assessing chemosensitivity in vitro and in vivo, and for assessing the parameters that modulate chemosensitivity in individual tumors. Chemosensitivity, Volume 1: In Vitro Assays provides a panel of 16 in vitro measures of chemosensitivity in adherent and non-adherent cells for single agents and combinations of agents. In addition to immunohistochemical and imaging approaches, these assays include clonogenic, colorimetric, fluorometric, and physiological assays. Highlights include image analysis to assess drug sensitivity, high throughput approaches using green fluorescent protein, DIMSCAN (a microcomputer fluorescence-based assay), and the ChemoFx assay used in biotechnology. A companion volume, Volume 2: In Vivo Models, Imaging, and Molecular Regulators, provides protocols for classifying tumors into response categories and customizing chemotherapy regimens to individual patients.

Chemosensitivity: Volume II: In Vivo Models, Imaging, and Molecular Regulators (Methods in Molecular Medicine #111)

A state-of-the art collection of readily reproducible laboratory methods for assessing chemosensitivity in vitro and in vivo, and for assessing the parameters that modulate chemosensitivity in individual tumors. Chemosensitivity,Volume 2: In Vivo Models, Imaging, and Molecular Regulators contains cutting-edge protocols for classifying tumors into response categories and for customizing therapy to individuals. These readily reproducible techniques allow measurements of DNA damage, apoptotic cell death, and the molecular and cellular regulators of cytotoxicity, as well as in vivo animal modeling of chemosensitivity. A companion volume, Volume 1: In Vitro Assays contains in vitro and in vivo techniques to identify which new agents or combination of agents are effective for each type of tumor.

Chemosensitivity Testing in Oncology (Recent Results in Cancer Research #161)

Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells.

Chemosensory Information Processing (Nato ASI Subseries H: #39)

In July 1989 a symposium was held at the Physiology Department of the Georg August University, G6ttingen, on the physiological, biophysical, biochemical, and technical principles of the coding of chemical substances both in nervous systems and artificial devices. This book is the collection of the papers presented at that meeting. Biological and artificial systems for odor coding both have in common that the stimulus selectivity of the receptor cells (sensors) is usually very poor, and the mechanisms which determine selectivity and sensitivity are largely unknown. However, a poor selectivity allows the coding of an enormous number of stimuli by combinations of receptor activities. In the field of chemosensory information coding there are thus two major problems: the function of the receptors and the network that processes and evaluates the primary information of the sensors. Accordingly, this volume has three parts: sensors, the network following the sensors, and the coding in this network. The expert secretarial assistance of M. Holtmann in preparing the camera-ready manuscript is gratefully acknowledged. D. Schild G6ttingen, August 1989 CONTENTS l. Response of olfactory receptor cells, isolated and in situ, to low concentrations of odorants 1 Stephan Frings, Bernd Lindemann 2. Excitation and adaptation of frog olfactory receptor neurones upon stimulation with second messengers and natural odorants 9 D. Schild, J. A. DeSimone, S. Hellwig 3. Receptor selectivity and dimensionality of odours at the stage of the olfactory receptor cells 21 GiJJes Sicard 4.

Chemotactic Cytokines: Biology of the Inflammatory Peptide Supergene Family (Advances in Experimental Medicine and Biology #305)

The existence of a new family of chemotactic cytokines was realised in 1987 following the isolation and structural determination by several groups of a peptide consisting of 72 amino acids which was a potent activator of neutrophils and a chemotactic agent for lymphocytes. The first symposium of this series was held at the Royal College of Surgeons of England in December 1988, entitled Novel Neutrophil Stimulating Peptides, and brought together the majority of the laboratories which had published in this area, see Immunology Today 10: 146-147(1989). Since the first symposium there has been a dramatic increase in our knowledge of the biology of this family of structurally related peptides. The Second International Symposium on Chemotactic Cytokines was held at the Royal College of Surgeons of England in June 1990. The aim of this symposium was to provide both a forum for discussion and to determine whether this knowledge can be utilised in the design of novel therapeutic strategies for the treatment of inflammatory disorders. Although the majority of studies have been concerned with the regulation of these peptides at the molecular and cellular level, there is now evidence to suggest that specific members of this superfamily have a role in the pathogenesis of a number of diverse diseases including arthritis, psoriasis, atherosclerosis, wound repair, inflammatory lung diseases and glomerulonephritis.

Chemotaxonomie der Pflanzen: Eine Übersicht über die Verbreitung und die systematische Bedeutung der Pflanzenstoffe (Lehrbücher und Monographien aus dem Gebiete der exakten Wissenschaften #14-35)

Chemotaxonomie der Pflanzen: Band XIb-2: Leguminosae Teil 3: Papilionoideae (Lehrbücher und Monographien aus dem Gebiete der exakten Wissenschaften #35)

Chemotaxonomie der Pflanzen: Eine Übersicht über die Verbreitung und die systematische Bedeutung der Pflanzenstoffe (Lehrbücher und Monographien aus dem Gebiete der exakten Wissenschaften #16)

Chemotaxonomie der Pflanzen (Lehrbücher und Monographien aus dem Gebiete der exakten Wissenschaften #33)

Chemotherapeutic Engineering: Collected Papers of Si-Shen Feng-A Tribute to Shu Chien on His 82nd Birthday

This book is a collection of the major publications of the authors in the emerging area of chemotherapeutic engineering. It describes and demonstrates the concept, feasibility, safety and prospect of chemotherapeutic engineering through a full spectrum of proof-of-concept experiments from design, characterization, in vitro cellular uptake, cytotoxi

Chemotherapeutic Strategy: Proceedings of the Symposium held on June 2–4 1982 at the World Trade Centre, London UK (pdf)

Chemotherapie: Ergebnisse, Probleme und Arbeitsmethoden

Dieser Buchtitel ist Teil des Digitalisierungsprojekts Springer Book Archives mit Publikationen, die seit den Anfängen des Verlags von 1842 erschienen sind. Der Verlag stellt mit diesem Archiv Quellen für die historische wie auch die disziplingeschichtliche Forschung zur Verfügung, die jeweils im historischen Kontext betrachtet werden müssen. Dieser Titel erschien in der Zeit vor 1945 und wird daher in seiner zeittypischen politisch-ideologischen Ausrichtung vom Verlag nicht beworben.

Chemotherapy (Cancer, a compresensive treatise #5)

The promise of chemotherapeutic control in the field of oncology seemed, in the beginning, no less bright than it had proven in the field of bacterial disease, and, therefore, its failures were felt all the more. Despite the serendipitous discoveries and inspired insights which tantalized us with striking remissions, or the rare tumors which proved to be fully susceptible to a given agent, in the main, there has been either total failure or a painfully slow acquisition of an armamentarium against a limited number of malignancies. To expect more, however, was the result of ignorance of the malignant cell, for, as has been described in the previous volumes of this series, the exploitable differences between malignant and normal cells are few or undiscovered. "Differences" is the "numerator" in this formula, but "exploitable" is the operational term, for, although a great number of differences bet\\\een normal and malignant cells have been described, rarely are these differences observed in a vital metabolic pathway or a crucial macromolecu­ lar structure. Essentially, the basic metabolic pathways and nutritional require­ ments for :lOrmal and malignant cells are the same, resulting in the fact that no chemotherapeutic agent can successfully inhibit a function in the majority of malignant cells without adversely affecting a similar function in the normal cell. It was, therefore, naive to expect a "magic bullet" which would select the malignant cell and destroy it.

Chemotherapy: Volume 7 Cancer Chemotherapy I (Chemotherapy #7)

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, pen­ icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es­ pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu­ losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur­ rent progress in chemotherapy.

Chemotherapy: Volume 8 Cancer Chemotherapy II (Chemotherapy #8)

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, exp~sion has been rapid, for example in cephalosporins, pen­ icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es­ pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is rece1v1ng increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu­ losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur­ rent progress in chemotherapy.

Chemotherapy: Volume 1 Clinical Aspects of Infections (Chemotherapy #1)

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, pen­ icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es­ pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu­ losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur­ rent progress in chemotherapy.

Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider

This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current chemotherapy and immunotherapy regimens for genitourinary malignancies and discusses indications, outcomes, and toxicities, as well as clinical trial concepts. Each of the book’s chapters offers a bulleted box of clinical pearls on the particular role of the APP.Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider is a resource for urologists, uro-radiologists, medical clinicians and family practitioners alike, familiarizing its audiences with systemic therapy regimens for urologic malignancies, as well as their expected outcomes and side effects.

Chemotherapy and Pharmacology for Leukemia in Pregnancy: Guidelines and Strategies for Best Practices

In response to the complexity involved in treating leukemia during pregnancy, and the need to find the most efficient treatment possible without harming the fetus, this book offers essential guidelines for institutions and practitioners alike. Pursuing a comprehensive approach, the book addresses a broad range of subjects, including: pregnancy and its characteristics; staging, pathology, morbidity and what to expect in each type of leukemia; chemotherapy for leukemia in pregnant women with complete trials; dose adjustment of chemotherapy for leukemia in pregnancy based on serum dosages; and pharmacokinetics and pharmacodynamics for this unique group of patients. In turn, subsequent chapters focus on protecting the fetus and neonatal management regarding chemotherapy for leukemia in pregnancy, including the treatment and risks for the fetus (for each type of leukemia), intrathecal therapy and its effects on the fetus; supportive drugs, antibiotics and antifungals for pregnant patients during chemotherapy, including intervention and dose adjustments; palliative care for women with leukemia in pregnancy; breastfeeding during treatment for leukemia; pharmacological aspects of supplements, vitamins and nutrition in pregnancy during leukemia treatment; and more. Combining contributions from highly qualified hematology professionals, who have pooled their knowledge to address the treatment of virtually every aspect of leukemia in pregnancy, the book is aimed at a complete pharmacological treatment, including guidelines and trials. It is a must-have not only for institutions providing care for hematology patients, but also for residency programs, research institutions, and professionals in areas that involve leukemia treatment for pregnant women — e.g. hematology, neonatology, obstetrics clinics, intensive medicine and critical care units.

Chemotherapy and Radiotherapy of Gastrointestinal Tumors (Recent Results in Cancer Research #79)

Attempts to influence survival of patients with colorectal cancer (CRC) by adjuvant chemotherapy are limited by the variability of survival in different prognostic groups [4] and the paucity of drugs that have shown activity in the advanced disease [10]. Of the few drugs which are active in the advanced disease, only 5-fluorouracil (5-FU) and razoxane «±1,2-bis(3,4-dioxopiperazin-1-yl)propane) are suitable for long-term adjuvant treatment [2, 9]. 5-FU has been widely and intensively studied as adjuvant chemotherapy in CRC [7], but there is no unanimity that it has even the marginal influence on survival that has been claimed [3, 10]. Razoxane has not previously been tested for adjuvant or maintenance treatment in CRC. It has however a number of biological activities which might be thought useful in the treatment of residual or minimal tumours [1] and which might therefore make it useful as an adjuvant. Thus it specifically prevents tumour dissemination and metastases in some tumours and normalizes the neovasculature which the tumours induce [6, 8, 11]. The drug is not cytotoxic in the usual sense, does not affect non-dividing cells, and only blocks cell division during a brief period of the cell cycle in late G and/or early mitosis [12]. It does so non-selectively and most cells capable of 2 division examined so far have been affected by the drug. Even affected cells however are not destroyed immediately, but may increase in size and become multinucleate [5].

Chemotherapy and Urological Malignancy (Clinical Practice in Urology)

Chemotherapy for malignant disease has brought about many rapid and often spectacular improvements in the survival rate of some groups of patients. Yet enthusiasm for these successes has, in part, been offset by the problems in evaluating responses to treatment and by the disappointment of failing to check the progress of still so many other tumours. These reactions will be no surprise to the medical historian but perhaps the expectations from scientific progress nowadays sometimes demand more than can reasonably be expected. Another expectation is that any review of chemotherapy is com­ pletely up to date, even prophetic. Such is the expansion of the subject that new drugs and trial results are continually being reported but it is this very mass of information that creates its own problems and makes many clinicians despair of finding a balanced judgement on all of this information. This was the challenge accepted by Professor Spiers. He then gathered together a group of colleagues who are amongst the acknowledged leaders in the field of chemotherapy for urological tumours, all of whom have made important contributions to this subject. However, each chapter is not merely a record of the author's experience but encompasses an assessment of past and present practice as well as perspectives in diagnosis and management. Almost all chapters include reference to published work up to and including 1981.

Chemotherapy for Gynecological Neoplasms: Current Therapy and Novel Approaches

Compiling an authoritative collection of research, recommendations, and guidelines from a highly regarded team of experts, this reference promotes a clear understanding of the chemotherapeutic management of cancer in each organ site of the lower female genital tract including the ovaries, fallopian tubes, uterus, vulva, and vagina.

Chemotherapy for Leukemia: Novel Drugs and Treatment

This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells. This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also oncologists, all physicians who specialize in blood cancer, and pharmacologists who are involved in the development of therapeutic agents for leukemia.

Chemotherapy in Neonates and Infants: Pharmacological Oncology for Children Under 1 Year Old

This book provides a comprehensive overview of pediatric oncology, discussing drug therapy and treatment in children under the age of 1 year. It is the first volume to focus on chemotherapy in newborns and infants, especially the daily clinical practice and treatment protocols. Intended as a practical manual, it addresses all the major topics related to pediatric oncology in an accessible and easy-to-use format. It examines topics in pediatric oncology therapeutics, including drug metabolism, excretion, toxicity, drugs that can be used for each week or month of the patient’s life, dose adjustment and treatment protocols.Chemotherapy in Neonates and Infants focuses on the safe treatment of children in the first year of life, and is aimed at pediatric oncology/hematology institutions, clinics and departments. It is particularly valuable for researchers, pediatric oncology physicians, pediatric and neonatology physicians, oncology pharmacists and the other healthcare professionals directly involved in the chemotherapy of neonates and infants.